Fig. 4: PPARG silencing inhibits tumor growth and angiogenesis in the ID8 xenograft model.
From: Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
A Photographs of representative mice from wild-type (WT) and Tie2-cre;PPARG KO mice. B, C Tumor weight (g) (B) and the number of tumor nodules (C). D, E Ki67 IHC (D) and CD31 IF (E) staining of tumors from WT versus PPARG KO mice. For statistical analysis, five randomly selected tumors per group were stained, and five random fields per tumor were scored. Scale bar = 200 µm for D and E. F Survival plot for B20, anti-VEGF antibody treatment. B20 was injected into the peritoneal cavity twice weekly at a dose of 5 mg/kg. G Expression of pAKT relative to AKT in tumor samples from WT versus Tie2-cre;PPARG KO mice (pAKT to AKT ratio determined after normalization of pAKT to AKT). Data represented as mean values ± SD, determined by two-tailed Student’s t-test; n = 3–4 mice for D, E, and G; n = 5 mice for B, C, and F.
